Combination Therapies Emerge in the Frontline for Renal Cell Carcinoma
Brad McGregor, MD, a medical oncologist at Dana-Farber Cancer Institute, discusses the future of combination therapies in the treatment landscape of renal cell carcinoma. He highlights the positive results from a few combinations that have been tested in clinical trials.
Brad McGregor, MD, a medical oncologist at Dana-Farber Cancer Institute, discusses the future of combination therapies in the treatment landscape of renal cell carcinoma (RCC). He highlights the positive results from a few combinations that have been tested in clinical trials.
A combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) was found to have response rates of 83% in patients who were previously untreated and over 60% in all patients with RCC in this particular trial, said McGregor.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
